MediCapital Rent Is Now Emsere
MediCapital Rent, a medical equipment solutions provider for clinical trials, today announced the company will begin operating under a new name, Emsere.
Emsere provides customers with proactive trial equipment solutions and manages those solutions with a single point of contact for all questions and support. Their global coverage with customs clearance and personalized study tracking of budget, inventory and delivery details provide exceptional, personalized service from study startup to study completion and all phases in between. Emsere’s equipment, supplies and software solutions extend to thousands of products, a rental fleet with over ten thousand devices and serving over 9,000 investigator sites to customers all over the world.
To read more about Emsere and their full range of capabilities, visit the company’s website.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
